AWM Investment Company Inc. acquired a new position in Benitec Biopharma Limited (NASDAQ:BNTC - Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 187,977 shares of the biotechnology company's stock, valued at approximately $2,515,000. AWM Investment Company Inc. owned about 0.55% of Benitec Biopharma as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors also recently made changes to their positions in the company. Suvretta Capital Management LLC grew its holdings in Benitec Biopharma by 16.9% in the 4th quarter. Suvretta Capital Management LLC now owns 11,548,351 shares of the biotechnology company's stock worth $155,556,000 after acquiring an additional 1,671,845 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its stake in shares of Benitec Biopharma by 7.5% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 2,120,672 shares of the biotechnology company's stock valued at $28,565,000 after acquiring an additional 148,148 shares during the last quarter. RA Capital Management L.P. bought a new position in shares of Benitec Biopharma during the fourth quarter valued at about $24,920,000. Nantahala Capital Management LLC boosted its holdings in shares of Benitec Biopharma by 23.9% during the fourth quarter. Nantahala Capital Management LLC now owns 1,038,371 shares of the biotechnology company's stock worth $13,987,000 after purchasing an additional 200,276 shares during the period. Finally, Vanguard Group Inc. grew its stake in shares of Benitec Biopharma by 2.4% in the third quarter. Vanguard Group Inc. now owns 992,114 shares of the biotechnology company's stock worth $13,919,000 after purchasing an additional 22,948 shares during the last quarter. Hedge funds and other institutional investors own 52.19% of the company's stock.
Analyst Upgrades and Downgrades
Several research analysts have commented on BNTC shares. Wall Street Zen upgraded shares of Benitec Biopharma from a "sell" rating to a "hold" rating in a report on Saturday, August 1st. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Benitec Biopharma in a research note on Friday, July 17th. Evercore assumed coverage on shares of Benitec Biopharma in a research report on Tuesday, May 12th. They set an "outperform" rating and a $25.00 price target on the stock. Guggenheim cut shares of Benitec Biopharma from a "buy" rating to a "neutral" rating in a research report on Wednesday, June 10th. Finally, Wedbush assumed coverage on shares of Benitec Biopharma in a research note on Tuesday, July 28th. They issued an "outperform" rating and a $16.00 price target for the company. Seven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $24.80.
Check Out Our Latest Stock Analysis on Benitec Biopharma
Benitec Biopharma Stock Performance
Shares of NASDAQ:BNTC opened at $13.02 on Wednesday. Benitec Biopharma Limited has a fifty-two week low of $9.85 and a fifty-two week high of $16.76. The business has a 50-day simple moving average of $12.69 and a two-hundred day simple moving average of $11.90. The firm has a market cap of $447.24 million, a price-to-earnings ratio of -11.42 and a beta of 0.28.
Benitec Biopharma Profile
(
Free Report)
Benitec Biopharma Ltd NASDAQ: BNTC is a clinical-stage biotechnology company developing gene-silencing therapies for serious human diseases. The company's proprietary DNA-directed RNA interference (ddRNAi) platform is designed to enable sustained expression of small RNA molecules that specifically target and silence disease-causing genes. By integrating RNAi sequences directly into DNA constructs, ddRNAi aims to provide a long-term therapeutic effect from a single administration.
Benitec's lead programs include development of ddRNAi candidates for chronic hepatitis B virus infection and for certain ocular conditions.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Benitec Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Benitec Biopharma wasn't on the list.
While Benitec Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
